AbbVie Enters Multi-Year Collaboration With Iambic To Accelerate Discovery And Development Of Small Molecule Therapies Across Immunology, Neuroscience And Oncology; Iambic To Receive Upfront Payment And Is Eligible For Milestone Payments And Tiered Royalties

The companies will leverage Iambic's AI platform to improve the efficiency and success of identifying promising new drug candidates."We are excited about the purpose-built AI capabilities Iambic is bringing to our Discovery scientists," said Nicholas Donoghoe, M.D., executive vice president and chief business and strategy officer, AbbVie. "We believe AI will be a powerful catalyst for scientific innovation across AbbVie. By equipping our teams with fit-for-purpose AI solutions, we can accelerate discovery, expand what is possible in R&D and significantly advance our commitment to making a remarkable impact for patients.""Combining Iambic's platform with the drug-hunting expertise of AbbVie scientists can help us make more precise decisions about the molecules we pursue," said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie. "The goal of our collaboration with Iambic is to design better molecules more efficiently and improve our probability of success, ultimately to deliver breakthrough medicines for patients sooner."In traditional small molecule discovery, scientists evaluate dozens of properties for each candidate individually. Iambic's molecular superintelligence platform is powered by Enchant and NeuralPLexer, technologies designed to optimize the full range of candidate properties simultaneously, increasing the chance of making better molecules while reducing drug discovery timelines.The collaboration will utilize Enchant v3, Iambic's next-generation multimodal transformer model that combines biomedical data modalities from across the drug discovery process and enables many drug design hypotheses to be tested in parallel and at scale. Enchant v3 is designed to achieve industry-leading prediction accuracy across drug discovery and development and is trained on over 6,000 molecular properties."Iambic's mission is to make better technology for better medicines — in our own hands and with partners," said Tom Miller, Ph.D., Co-Founder and CEO, Iambic. "We are eager to bring Iambic's molecular superintelligence platform to bear alongside AbbVie's world-class team to address unmet patient need. We anticipate an impactful collaboration — for Iambic, for AbbVie, and for the patients we serve."Under the terms of the collaboration, Iambic will receive an upfront payment and is eligible to receive success-based milestone payments and tiered royalties on net sales from products generated from the collaboration.